9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for patients with rare gastrointestinal diseases. Founded in 2018, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of drug development and clinical research. With a robust pipeline that includes unique oral therapies, 9 Meters Biopharma is dedicated to addressing unmet medical needs in conditions such as short bowel syndrome and celiac disease. Their flagship product, a novel treatment for short bowel syndrome, showcases their commitment to advancing patient care through cutting-edge science. Recognised for its rapid progress and strategic partnerships, 9 Meters Biopharma is positioned as a leader in the biopharma sector, striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does 9 Meters Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
9 Meters Biopharma, Inc.'s score of 31 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
9 Meters Biopharma, Inc.'s reported carbon emissions
9 Meters Biopharma, Inc., headquartered in the US, currently does not report any specific carbon emissions data. However, the company has set ambitious climate commitments aimed at reducing greenhouse gas (GHG) emissions. By 2025, 9 Meters Biopharma aims to achieve a 30% reduction in combined Scope 1 and Scope 2 GHG emissions per square metre, using a 2016 peak baseline as a reference. This target reflects the company's commitment to improving energy efficiency and reducing its carbon footprint in its operations. Additionally, the company is aligned with broader industry trends, as seen in commitments from related organisations. For instance, Pfizer, a significant player in the biopharma sector, has pledged to become carbon neutral across its internal operations by 2030, targeting a 46% absolute reduction in Scope 1 and Scope 2 emissions from a 2019 baseline. Pfizer also aims to reduce upstream logistics emissions by 10% and business travel emissions by 25% by 2025, both from a 2019 baseline. While 9 Meters Biopharma has not disclosed specific emissions figures, its reduction initiatives indicate a proactive approach to climate action, aligning with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Scope 1 | 222,286,000 | 000,000,000 | - | - | - |
| Scope 2 | 117,362,000 | 000,000,000 | - | - | - |
| Scope 3 | - | - | 000,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
9 Meters Biopharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
